Insulin Therapy for the Management of Hyperglycemia in Hospitalized Patients

Marie E. McDonnell, Boston University
Guillermo Umpierrez, Emory University

Journal Title: Endocrinology and Metabolism Clinics of North America
Volume: Volume 41, Number 1
Publisher: Elsevier: 12 months | 2012-03, Pages 175-201
Type of Work: Article | Post-print: After Peer Review
Publisher DOI: 10.1016/j.ecl.2012.01.001
Permanent URL: http://pid.emory.edu/ark:/25593/fjk78

Final published version: http://dx.doi.org/10.1016/j.ecl.2012.01.001

Copyright information:
© 2012 Elsevier Inc. All rights reserved.

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommerical-NoDerivs 3.0 Unported License (http://creativecommons.org/licenses/by-nc-nd/3.0/).

Accessed September 27, 2023 7:30 PM EDT
Insulin Therapy for the Management of Hyperglycemia in Hospitalized Patients

Marie E. McDonnell, MD\textsuperscript{a} and Guillermo E. Umpierrez, MD\textsuperscript{b,\textsuperscript{*}}

\textsuperscript{a}Department of Medicine, Boston University School of Medicine, 88 East Newton Street, Boston, MA 02118, USA

\textsuperscript{b}Department of Medicine, Emory University School of Medicine, 49 Jesse Hill Jr. Drive, Atlanta, GA 30303, USA

Abstract

It has long been established that hyperglycemia with or without a prior diagnosis of diabetes increases both mortality and disease-specific morbidity in hospitalized patients\textsuperscript{1–4} and that goal-directed insulin therapy can improve outcomes.\textsuperscript{5–9} During the past decade, since the widespread institutional adoption of intensified insulin protocols after the publication of a landmark trial,\textsuperscript{5,10} the pendulum in the inpatient diabetes literature has swung away from achieving intensive glucose control and toward more moderate and individualized glycemic targets.\textsuperscript{11,12} This change in clinical practice is the result of several factors, including challenges faced by hospitals to coordinate glycemic control across all levels of care,\textsuperscript{13,14} publication of negative prospective trials,\textsuperscript{15,16} revised recommendations from professional organizations,\textsuperscript{17,18} and increasing evidence on the deleterious effect of hypoglycemia.\textsuperscript{19–22} This article reviews the pathophysiology of hyperglycemia during illness, the mechanisms for increased complications and mortality due to hyperglycemia and hypoglycemia, beneficial mechanistic effects of insulin therapy and provides updated recommendations for the inpatient management of diabetes in the critical care setting and in the general medicine and surgical settings.\textsuperscript{23,24}

Keywords

Inpatient diabetes; Hyperglycemia; Hypoglycemia; Critical illness; Hospital; Nutrition

PREVALENCE OF HYPERGLYCEMIA AND DIABETES IN HOSPITALIZED PATIENTS

The prevalence of diabetes around the world is alarmingly high and is growing. In 2007, it was estimated that approximately 23.6 million people in the United States had diabetes, approximately 7.8\% of the population, of whom 90\% to 95\% of these had type 2 diabetes mellitus.\textsuperscript{25} Patients with diabetes have a 3-fold greater chance of hospitalization compared with those without diabetes,\textsuperscript{26,27} and it is estimated that more than 20\% of all adults discharged have diabetes, with 30\% of them requiring 2 or more hospitalizations in any given year.\textsuperscript{4,26,27}

The exact prevalence of hospital hyperglycemia is not known but it varies based on study populations and definitions used in previous reports. Observational studies have reported a
prevalence of hyperglycemia ranging from 32% to 38% in community hospitals to approximately 70% of diabetic patients with acute coronary syndrome and approximately 80% of cardiac surgery patients in the perioperative period. Patients with newly identified, or “stress,” hyperglycemia may be at the highest risk of hyperglycemia-related morbidity and mortality. The American Diabetes Association (ADA) and American Association of Clinical Endocrinologists (AACE) consensus on inpatient hyperglycemia defined stress hyperglycemia or hospital-related hyperglycemia as any blood glucose (BG) concentration greater than 7.8 mmol/L (140 mg/dL). Although stress hyperglycemia typically resolves as the acute illness or surgical stress abates, it is important to identify and track patients because 60% of patients admitted with new hyperglycemia had confirmed diabetes at 1 year. Cross-sectional studies of patients without a known history of diabetes with hyperglycemia revealed that between 30% and 60% of patients have impaired carbohydrate intolerance or diabetes during follow-up. Until recently, clinical guidelines recommended that all patients with stress hyperglycemia should be tested with an oral glucose tolerance test shortly after discharge to assess carbohydrate tolerance. More recently, the use of the hemoglobin A1c (HbA1c) test has been recommended versus the oral glucose tolerance test as the preferred diagnostic testing in hospitalized patients with hyperglycemia. Measurement of HbA1c levels during periods of hospitalization provides an opportunity to differentiate patients with stress hyperglycemia from those with diabetes who were previously undiagnosed and to identify patients with known diabetes who would benefit from intensification of their glycemic management regimen. The ADA recommendations indicate that patients with HbA1c level of 6.5% or higher can be identified as having diabetes.

PATHOPHYSIOLOGY OF HYPERGLYCEMIA DURING ILLNESS

Hyperglycemia is a frequent manifestation of critical and surgical illness, resulting from the acute metabolic and hormonal changes associated with the response to injury and stress. Acute illness, surgery, and trauma raise levels of stress mediators, namely stress hormones, cytokines, and central nervous system, that interfere with carbohydrate metabolism, leading to excessive hepatic glucose output and reduced glucose uptake in peripheral tissues. In addition, acute illness increases proinflammatory cytokines, which increase insulin resistance by interfering with insulin signaling.

Regulation of Blood Glucose in Healthy Individuals

Maintenance of a constant BG level is essential for normal physiology in the body, particularly for the central nervous system. The brain can neither synthesize nor store the amount of glucose required for normal cellular function. In the postabsorptive state, systemic glucose balance is maintained, and hypoglycemia and hyperglycemia are prevented, by dynamic, minute-to-minute regulation of endogenous glucose production from the liver and kidneys and of glucose use by peripheral tissues (Fig. 1). Glucose production is accomplished by gluconeogenesis or glycogenolysis. By way of gluconeogenesis, noncarbohydrate precursors, such as lactate, alanine, and glycerol, are converted to glucose. Excess glucose is polymerized to glycogen, which is mainly stored in the liver and muscle. Glycogenolysis breaks down glycogen to the individual glucose units for mobilization during times of metabolic need. These steps are dependent on the interaction of different mechanisms, including glucoregulatory hormones (insulin and counterregulatory hormones) and gluconeogenic substrate supply (lactate, glycerol, and amino acids). Insulin is the main glucoregulatory hormone and inhibits hepatic glucose production and stimulates peripheral glucose uptake. In the liver, insulin directs glucose-6-phosphate to glycogen by increasing the activity of glycogen synthase and decreasing the activity of glycogen phosphorylase, which stimulates the breakdown of glycogen to glucose. In addition, insulin inhibits gluconeogenesis by inhibiting gene
transcription and expression of phosphoenolpyruvate carboxykinase, the rate-limiting step in hepatic gluconeogenesis,\textsuperscript{40,41} and by increasing the transcription of pyruvate kinase, the main glycolytic enzymes that produces pyruvate molecules, the final product of aerobic glycolysis.\textsuperscript{42}

### Pathogenesis of Hyperglycemia During Stress and Illness

Given the obligatory role of glucose to maintain normal physical function, it is not surprising that the normal response to stress or illness includes the release of counterregulatory hormones, which counteract insulin to increase the availability of glucose.\textsuperscript{43} Counterregulatory hormones leads to several alterations in carbohydrate metabolism, including insulin resistance, increased hepatic glucose production, impaired peripheral glucose use, and relative insulin deficiency. In addition, high epinephrine levels stimulate glucagon secretion and inhibit insulin release by pancreatic $\beta$ cells (Table 1).\textsuperscript{44} High cortisol levels increase hepatic glucose production, stimulate protein catabolism, and increase circulating amino acids concentration, providing precursors for gluconeogenesis.\textsuperscript{45,46}

Acute stress increases proinflammatory cytokines, such as tumor necrosis factor (TNF)-$\alpha$, interleukin (IL)-6, and IL-1,\textsuperscript{34,47–49} which increase insulin resistance by interfering with insulin signaling. TNF-$\alpha$ activates c-Jun N-terminal kinase, a signaling protein molecule that phosphorylates insulin receptor substrate-1 and prevents insulin-mediated activation of phosphatidylinositol 3-kinase involved in tissue glucose uptake. Downstream effect process decreases insulin stimulation of glucose uptake and causes hyperglycemia.\textsuperscript{50,51}

### Mechanisms of Detrimental Effects of Hyperglycemia

Although there are still no proved mechanisms to explain the detrimental effects of hyperglycemia in critically ill patients, several mechanisms may explain the higher risk of complications and mortality in hyperglycemic patients in the hospital (see Fig. 1). Severe hyperglycemia causes osmotic diuresis that leads to hypovolemia, decreased glomerular filtration rate, and prerenal azotemia. Hyperglycemia has also been shown to increase rate of hospital infections and poor wound healing.\textsuperscript{52,53} Hyperglycemia is associated with impaired leukocyte function, including decreased phagocytosis, impaired bacterial killing, and chemotaxis.\textsuperscript{54} Hyperglycemia has also been shown to impair collagen synthesis and to impair wound healing among patients with poorly controlled diabetes.\textsuperscript{52} In addition, acute hyperglycemia results in nuclear factor $\kappa$B (NF-$\kappa$B) activation and production of inflammatory cytokines, such as TNF-$\alpha$, IL-6, and plasminogen activator inhibitor-1, which cause increased vascular permeability and leukocyte and platelet activation.\textsuperscript{55}

Acute hyperglycemia activates oxidative pathway through increased generation of reactive oxygen species (ROS). ROS and the cellular redox state are increasingly thought to be responsible for affecting different biologic signaling pathways. ROS are formed from the reduction of molecular oxygen or by oxidation of water to yield products, such as superoxide anion, hydrogen peroxide, and hydroxyl radical: the mitochondria and NADP oxidase are the major sources of ROS production.\textsuperscript{56} In moderate amounts, ROS are involved in several physiologic processes that produce desired cellular responses. Large quantities of ROS, however, can lead to cellular damage of lipids, membranes, proteins, and DNA.\textsuperscript{57} Oxidative stress activates a series of stress pathways involving a family of serine/threonine kinases, which in turn have a negative effect on insulin signaling. Oxidative stress has also been implicated as a contributor to $\beta$-cell and mitochondrial dysfunction, which can lead to the development and worsening of hyperglycemia.\textsuperscript{57}
In patients with acute ischemic cardiac events, acute hyperglycemia has been shown to attenuate ischemic preconditioning of the heart, a protective mechanism for ischemic injury, possibly by inhibiting activation of ATP-sensitive potassium channels that activates glycolysis. Increasing evidence indicates that hyperglycemia may induce cardiac myocyte death through apoptosis or by exaggerating ischemia-reperfusion cellular injury. High glucose concentrations also have deleterious effect on endothelial function by suppressing formation of nitric oxide and impairing endothelium-dependent flow-mediated dilation. In addition, hyperglycemia induces abnormalities in hemostasis, including increased platelet activation, adhesion, and aggregation; reduced plasma fibrinolytic activity; and increased plasminogen activator inhibitor-1 activity. Adding to the effects of hyperglycemia in acute coronary syndrome, high free fatty acid (FFA) levels seen in diabetes and stress can also aggravate ischemia/reperfusion damage by limiting the ability of cardiac muscle to uptake glucose for anaerobic metabolism. Although FFAs are the normal substrate of choice for healthy myocardium, high FFA levels are toxic to an ischemic myocardium, leading to cardiac arrhythmias, sympathetic overactivity, increased blood pressure, oxidative stress, and endothelial dysfunction. Increased FFAs also produce dose-dependent insulin resistance in peripheral tissues and increase hepatic glucose output in both diabetic and nondiabetic individuals.

In patients with ischemic stroke, hyperglycemia has been shown to aggravate neuronal damage after brain ischemia. During the progression of stroke, the area of ischemic penumbra (the region of the brain tissue surrounding the core of infarcted tissue where neurons still viable) is more sensitive to ischemic injury. Studies using animal models of stroke have shown that hyperglycemia decreases reperfusion to the ischemic tissue and increases infarct volumes compared with normoglycemia. Hemispheric cerebral blood flow has been shown reduced by as much as 37% in hyperglycemia compared with normoglycemia. Increased tissue acidosis due to accumulation of lactate in the ischemic brain mediates ischemic injury by enhancing lipid peroxidation and free radical formation, accumulation of intracellular calcium, and impairing mitochondrial function.

HYPERGLYCEMIA IN ACUTE ILLNESS: RATIONALE FOR PROACTIVE TREATMENT

Extensive observational and prospective randomized trials in patients with critical illness indicate a strong association between hyperglycemia and poor clinical outcome, such as mortality, morbidity, length of stay, infections, and overall complications. This association is well documented on admission and also for the mean glucose level during the hospital stay. Cross-sectional studies have shown that the risk of complications and mortality relates to the severity of hyperglycemia, with a higher risk observed in patients without a history of diabetes (new-onset and stress-induced hyperglycemia) compared with those with a known diagnosis of diabetes.

Glycemic Control Trials in Critical Care Setting

A large retrospective cohort study of more than 250,000 veterans admitted to various ICUs in the United States found that the development of hyperglycemia is an independent risk for mortality in individuals with cardiac diagnoses, sepsis, and respiratory failure. In cardiac surgery patients, perioperative hyperglycemia has been associated with increased length of stay, delayed extubation, increased risk of perioperative complications, and mortality. Similarly, several observational studies and meta-analyses in patients with myocardial infarction and with stroke and subarachnoid hemorrhage have consistently reported that hyperglycemia on admission or during the hospital stay is associated with poor clinical outcome and a higher risk of mortality, independently from other predictors of a
poor prognosis, such as age and diabetic status. In a nonrandomized, prospective study, Furnary and colleagues followed 3554 patients with diabetes who underwent coronary artery bypass graft and were treated with either subcutaneous insulin or continuous insulin infusion (CII) for hyperglycemia. Compared with patients treated with subcutaneous insulin who had average BG level of 11.9 mmol/L (214 mg/dL), patients treated with CII with average BG level of 9.8 mmol/L (177 mg/dL) had significantly less deep sternal wound infections and a reduction in risk-adjusted mortality by 50%.

A follow-up analysis in a subset of this study population revealed that patients with BG levels greater than 11.1 mmol/L (>200 mg/dL) had higher mortality (5.0% vs 1.8%, P < .001) than those with BG levels less than 11.1 mmol/L. Similarly, the Leuven surgical ICU study reported that intensive therapy to maintain target glucose levels 4.4 mmol/L to 6.1 mmol/L (80–110 mg/dL) compared with conventional therapy to maintain target levels between 10 mmol/L and 11.1 mmol/L (180–200 mg/dL) significantly reduced the frequency of bacteremia, antibiotic requirements, length of ventilator dependency, number of ICU days, and an overall mortality (34% reduction).

In a different study, these investigators following the same protocol in medical ICU patients also reported less ICU and hospital mortality after 3 days of treatment with CII.

Recent randomized controlled trials, however, have shown that intensive glycemic control (target glucose <110 mg/dL) has been difficult to achieve without increasing the risk for severe hypoglycemia, causing some to be discontinued early (Table 2). In addition, several multicenter trials have failed to show significant improvement in clinical outcome or have resulted in increased mortality risk. The largest and recent Normoglycemia in Intensive Care Evaluation Survival Using Glucose Algorithm Regulation (NICE-SUGAR) trial, with more than 6000 subjects from different ICUs, randomized patients to receive either conventional glycemic control (<10 mmol/L [<180 mg/dL]) or intensive glycemic control (4.5–6 mmol/L [81–108 mg/dL]) and reported that intensive glycemic control was associated with increased mortality at 90 days (24.9% vs 27.5%, P = .02) and higher incidence of hypoglycemia (6.8% vs 0.5%, P < .001).

**Hyperglycemia and Noncritical Illness**

The importance of hyperglycemia also applies to non–critically ill patients admitted to general medicine and surgery services. In such patients, hyperglycemia is associated with poor hospital outcomes, including prolonged hospital stay, infections, disability after hospital discharge, and death. In a retrospective study of 1886 patients admitted to a community hospital, mortality was significantly higher in patients with newly diagnosed hyperglycemia and those with known diabetes compared with those with normoglycemia (10% vs 1.7% vs 0.8%, respectively; P < .01). Admission hyperglycemia has also been linked to worse outcomes in patients with community-acquired pneumonia. In a prospective cohort multicenter study of 2471 patients, those with admission glucose levels greater than 11 mmol/L (198 mg/dL) had a greater risk of mortality and complications than those with glucose less than 11 mmol/L. The risk of in-hospital complications increased 3% for each 1 mmol/L increase in admission glucose. In a retrospective study of 348 patients with chronic obstructive pulmonary disease and respiratory tract infection, the relative risk of death was 2.10 in those with a BG levels of 7 mmol/L to 8.9 mmol/L (126–160 mg/dL) and 3.42 for those with BG levels greater than 9.0 mmol/L (162 mg/dL) compared with patients with BG levels 6.0 mmol/L (110 mg/dL). Furthermore, each 1 mmol/L increase in BG level was associated with a 15% increase in the risk of an adverse clinical outcome, which was defined as death or length of stay of greater than 9 days.

Several observational studies in general surgery patients admitted to noncritical care areas have also shown that hyperglycemia is associated with increased risks of perioperative complications, length of stay, and mortality. Patients with glucose levels of 5.6 mmol/L...
to 11.1 mmol/L (110–200 mg/dL) and those with glucose levels greater than 11.1 mmol/L (>200 mg/dL) had, respectively, a 1.7-fold and 2.1-fold increased mortality compared with those with glucose levels less than 5.6 mmol/L (<110 mg/dL). General surgery patients with glucose levels greater than 12.2 mmol/L (>220 mg/dL) on the first postoperative day had a 2.7-times increased rate of infection. The risk of postoperative infection rate in patients undergoing noncardiac general surgery was estimated to increase by 30% for every 2.2 mmol/L (40 mg/dL) rise in the presence of hyperglycemia. A recent study in 3184 general surgery patients in non-ICU setting reported a strong association between presurgery and postsurgery hyperglycemia and postoperative cases of pneumonia, systemic blood infection, urinary tract infection, acute renal failure, and acute myocardial infarction. In that study, multivariate analysis adjusted for age, gender, race, and surgery severity found that the risk of death increased in proportion to perioperative glucose levels; however, this association was significant only for patients without a history of diabetes compared with patients with a known history of diabetes. Patients without a history of diabetes (stress hyperglycemia) experiencing worse outcome and higher mortality at a same glucose level than those with known history of diabetes suggests a lack of adaptation to acute hyperglycemia and its associated inflammatory and oxidative state.

Beneficial Mechanistic Effects of Insulin Therapy

The adverse outcomes associated with hyperglycemia may be attributed to the inflammatory and pro-oxidant effects observed with increased glucose levels. Many of the adverse outcomes can be prevented by administration of insulin. The positive effects of insulin administration are attributed to its anti-inflammatory, vasodilatory, and antioxidant effects as well as its ability to inhibit lipolysis and platelet aggregation. Several studies have reported that elevated levels of cytokines and inflammatory markers associated with severe hyperglycemia return to normal shortly after the treatment with insulin and resolution of hyperglycemia. Insulin acts to suppress counterregulatory hormones and proinflammatory transcription factors and may even suppress the formation of ROS. Insulin suppresses the proinflammatory transcription factors, NF-κB and early growth response-1. Recent studies have also shown that insulin administration is associated with a decrease in the concentration of compounds whose gene transcription is modulated by these factors, including plasminogen activator inhibitor-1, intercellular adhesion molecule-1, monocyte chemotactic protein-1, and monocyte chemotactic protein-9. Additionally, insulin induces vasodilation and inhibits lipolysis and platelet aggregation. The vasodilation that accompanies insulin administration may be attributed to its ability to stimulate nitric oxide release and induce the expression of endothelial nitric oxide synthase.

GLYCEMIC TARGETS IN ICU AND NON-ICU SETTINGS

The AACE/ADA Task Force on Inpatient Glycemic Control recommended targeting a BG level between 7.8 mmol/L and 10.0 mmol/L (140 and 180 mg/dL) for the majority of ICU patients and lower glucose targets between 6.1 mmol/L and 7.8 mmol/L (110 and 140 mg/dL) in selected ICU patients (ie, centers with extensive experience and appropriate nursing support, cardiac surgical patients, and patients with stable glycemic control without hypoglycemia). Glucose targets greater than 10 mmol/L (>180 mg/dL) or less than 6.1 mmol/L (<110 mg/dL) are not recommended in ICU patients due to lack of proved benefit and potential risk in both large and small prospective randomized trials (see Table 2).

In non-ICU settings, the AACE/ADA Practice Guideline recommends a premeal glucose level less than 140 mg/dL (7.8 mmol/L) and a random BG level less than 10.0 mmol/L (180 mg/dL) for the majority of non–critically ill patients treated with insulin. To avoid hypoglycemia (<3.9 mmol/L), the total basal and prandial insulin dose should be reduced if glucose levels fall between less than 3.9 mmol/L and 5.6 mmol/L (70–100 mg/
dL). In contrast, higher glucose ranges may be acceptable in terminally ill patients or in patients with severe comorbidities as well as in those in patient-care settings where frequent glucose monitoring or close nursing supervision is not feasible.\textsuperscript{18,96,97} In such patients, however, it is prudent to maintain a reasonable degree of glycemic control (BG <11.1 mmol/L [200 mg/dL]) as a way of avoiding symptomatic hyperglycemia.

**MANAGING HYPERGLYCEMIA IN THE HOSPITAL ENVIRONMENT**

Despite solid evidence in support of glycemic control in hospitalized patients, BG control continues to be deficient and is frequently overlooked in critically ill patients and in general medicine and surgery services.\textsuperscript{4,98} Many factors could explain the physician’s inactivity in addressing in-hospital hyperglycemia. First, hyperglycemia is rarely the focus of care during the hospital stay, because the overwhelming majority of hospitalizations in patients with hyperglycemia occur for comorbid conditions.\textsuperscript{4,99} Second, fear of hypoglycemia constitutes a major barrier to efforts to improve glycemic control in hospitalized subjects, especially in patients with poor caloric intake.\textsuperscript{100} Third, in the presence of altered nutrition and associated medical illness, physicians frequently hold a patient’s previous outpatient diabetes regimen and initiate sliding scale coverage with regular insulin. Finally, the specific morbidities due to secondary causes of hyperglycemia, such as steroid-exacerbated hyperglycemia, remain largely unknown.\textsuperscript{101} Hospital care of patients with diabetes and hyperglycemia is complex, involving multiple providers with varying degrees of expertise who are dispersed across many different areas of the hospital. A multidisciplinary systems approach with identifiable hospital champions can help guide meaningful progress away from clinical inertia and toward safe glycemic control, insulin management, and hypoglycemia prevention.\textsuperscript{18,102}

**Glucose Monitoring in Hospital**

Bedside capillary point of care (POC) testing is the preferred method for guiding ongoing glycemic management of individual patients.\textsuperscript{18} POC testing is usually performed 4 times a day: before meals and at bedtime for patients who are eating.\textsuperscript{53,96} For patients who are restricted to nothing by mouth or are receiving continuous enteral nutrition, POC testing is recommended every 4 to 6 hours. More frequent glucose monitoring is indicated in patients treated with continuous intravenous insulin infusion\textsuperscript{103,104} or after a medication change that could alter glycemic control (eg, corticosteroid use or abrupt discontinuation of enteral or parenteral nutrition)\textsuperscript{101,105,106} or in patients with frequent episodes of hypoglycemia.\textsuperscript{101,105}

Health care workers should keep in mind that the accuracy of most hand-held glucose meters is far from optimal.\textsuperscript{107} There is an accepted variance between meter readings and central laboratory results (up to 20% allowed by Food and Drug Administration regulations),\textsuperscript{96,108} which can potentially lead to inappropriate therapy. Many patient factors are known to affect the accuracy of the POC testing including pH changes, oxygenation status, and low hematocrit, among others.\textsuperscript{107,109}

**Medical Nutrition Therapy in Hospitalized Patients with Diabetes**

Medical nutrition therapy (MNT) plays an important role in management of hyperglycemia in hospitalized patients with diabetes mellitus and often requires specifically designed insulin programs. The goals of inpatient MNT for patients with diabetes are to help optimize glycemic control, provide adequate calories to meet metabolic demands, address individuals needs based on personal food preferences, and provide a discharge plan for follow-up care.\textsuperscript{53,97,110} MNT in the hospital can be challenging in the presence of acute medical illness, poor appetite, inability to eat, increased nutrient and calorie needs due to catabolic stress, and variation in diabetes medications.
The metabolic needs of most hospitalized subjects can be supported by providing 25 to 35 cal/kg/d\textsuperscript{111,112} whereas critically ill patients require less caloric intake at 15 to 25 cal/kg/d\textsuperscript{113} This translates into a diet on average containing 1800 to 2000 cal/d\textsuperscript{53} or a diet containing approximately 200 g/d of carbohydrates divided between meals.\textsuperscript{112} Care must be taken not to overfeed patients because this can exacerbate hyperglycemia. There is no single meal planning system that is ideal for hospitalized patients. It is suggested, however, that hospitals consider implementing a consistent carbohydrate diabetes meal-planning system.\textsuperscript{112} This systems uses meal plans without a specific calorie level but with consistency in the carbohydrate content of meals. The carbohydrate components of breakfast, lunch, dinner, and snacks may vary, but the day-to-day carbohydrate content of specific meals and snacks is kept constant.\textsuperscript{53,112} It is recommended that the term, ADA diet, no longer be used, because the ADA no longer endorses a single nutrition prescription or percentages of macronutrients.\textsuperscript{112}

Patients requiring clear or full liquid diets should receive approximately 200 g/day of carbohydrates in equally divided amounts at meal and snack times. Liquids should not all be sugar-free because patients require sufficient carbohydrate and calories, and sugar-free liquids do not meet these nutritional needs. After surgery, food intake should be initiated as quickly as possible with progression from clear liquids to full liquids to solid foods as rapidly as tolerated.\textsuperscript{112,114} Increasing evidence, however, indicates that early enteral feeding in the perioperative period is safe and well tolerated and results in reduction of wound morbidity and healing, fewer septic complications, diminished weight loss, and improved protein kinetics.\textsuperscript{114}

**Enteral Nutrition**

Although the majority of non–critically ill hospitalized patients receive nutrition support as 3 discrete meals with or without scheduled snacks each day, some patients may require enteral nutrition support. Standard enteral formulas reflect the reference values for macronutrients and micronutrients for a healthy population and contain 1 to 2 calories per milliliter. Standard diabetes-specific formulas provide low amounts of lipids (30% of total calories) combined with a high carbohydrate content (55%–60% of total calories); however, newer diabetic formulas have replaced part of carbohydrates with monounsaturated fatty acids (up to 35% of total calories), 10 g/L to 15 g/L dietary fiber, and up to 30% fructose.\textsuperscript{115,116} Several outpatient and inpatient studies in subjects with type 2 diabetes mellitus have reported better glycemic control (lower mean, fasting, and/or postprandial glucose levels), a trend toward decreased HbA1c levels, and lower insulin requirements with a low-carbohydrate, high–monounsaturated fatty acids (LCHM) formulas compared with a standard high-carbohydrate formulas.\textsuperscript{117,118} In a meta-analysis of studies comparing enteral LCHM formulas with standard formulations, the postprandial glucose rise was reduced by 18 mg/dL to 29 mg/dL with the newer formulations.\textsuperscript{119}

**Parenteral Nutrition**

The beneficial effect of parenteral nutrition in improving the nutritional status of critically ill patients is well established.\textsuperscript{120} Recent randomized trials and meta-analyses, however, have suggested that parenteral nutrition may be associated with increased risk of infectious complications and mortality in critically ill patients.\textsuperscript{120,121} In addition, its use has been linked to aggravation of hyperglycemia independent of a prior history of diabetes.\textsuperscript{121,122} BG level measures above 150 mg/dL before and within 24 hours of initiation of parenteral nutrition are predictors of both increased inpatient complications and hospital mortality. Although randomized controlled studies to guide effective and safe administration of insulin during parenteral nutrition are lacking, patients with or without history of diabetes with persistent hyperglycemia (≥140 mg/dL) should be treated with insulin therapy. To correct
hyperglycemia, regular insulin can be added to parenteral nutrition solutions or can be given as continuous insulin infusion.

**PHARMACOLOGIC TREATMENT OF INPATIENT HYPERGLYCEMIA**

Insulin, given either intravenously or subcutaneously, is the preferred regimen for effectively treating hyperglycemia in the hospital. The use of oral antidiabetic agents should be avoided in the hospital setting because no data are available on their safety and efficacy in the inpatient setting. Major limitations to the use of oral agents for hospital use are their slow onset of action that does not allow rapid glycemic control and dose adjustments to meet the changing needs of acutely ill patients and risk of hypoglycemia with insulin secretagogues. Sulfonylureas may increase the risk of hypoglycemia in hospitalized patients with poor appetite or ordered dietary restrictions. In addition, they may worsen cardiac and cerebral ischemia by inhibiting ATP-sensitive potassium channels, resulting in cell membrane depolarization and increased intracellular calcium concentration. Many patients have one or more contraindications to the use of metformin on admission, including acute congestive heart failure, renal or liver dysfunction, and chronic pulmonary disease. The use of thiazolidinediones is limited because they can increase intravascular volume and may precipitate or worsen congestive heart failure and peripheral edema. Despite their benign side-effect profile and single oral daily dose of dipeptidyl peptidase-IV inhibitors, these agents have a minor reduction in glucose concentration, and no previous studies have assessed their efficacy and safety in hospitalized patients.

**Insulin Therapy in Critical Care**

In the critical care setting, a variety of CII protocols have been shown effective in achieving glycemic control and in improving hospital outcome with a low-rate of hypoglycemic events. In most patients, CII lowers BG levels to target range in approximately 4 to 8 hours and allows for rapid titration of dose for both anticipated (eg, initiation or discontinuation of vasopressors) or unanticipated (eg, acute deteriorations in clinical status) changes in clinical status. Essential elements that increase protocol success of CII are (1) rate adjustment considers the current and previous glucose value and the current rate of insulin infusion, (2) rate adjustment considers the rate of change (or lack of change) from the previous reading, and (3) frequent glucose monitoring (hourly until stable glycemia is established, and then every 2–3 h) (Fig. 2). BG level greater than 140 mg/dL should trigger initiation of insulin therapy, titrated to maintain glucose values absolutely between 140 mg/dL and 180 mg/dL while avoiding hypoglycemia. Using a higher trigger value to start insulin treatment could allow excursion to glucose values above 180 mg/dL, which is undesirable with respect to the immunosuppressive effects.

Recently, computer-based algorithms aiming to direct the nursing staff in adjusting insulin infusion rates have become commercially available. Controlled trials have reported more rapid and tighter glycemic control with computer-guided algorithms than with standard paper form protocols in ICU patients. Use of computer-based algorithms has been associated with lower glycemic variability and a higher percentage of BG level readings within target range than treating patients with the standard regimen. The clinical importance of the degree of variability and rapidity of fluctuations in glucose levels in critically ill patients is a topic of recent interest because it has been identified as an independent contributor to the risk of mortality in critically ill patients. Despite differences in glycemic control between insulin algorithms, no clinical outcome differences have been reported in the frequency of severe hypoglycemic events, length of ICU and hospital stay, or mortality. Thus, most insulin algorithms seem appropriate alternatives for the management of hyperglycemia in critically ill patients, and the choice depends on physician preferences and cost considerations.
The use of subcutaneous insulin has not been formally studied in ICU patients and should be avoided in critical ill patients, in particular during hypotension or shock. Many factors can affect insulin absorption during critical illness and in the perioperative period. The net of these factors is increased potential for overlapping dose effects, administration timing errors, and unexpected hypoglycemia.

Transition from Intravenous Insulin Infusion to Subcutaneous Insulin

All patients with type 1 diabetes mellitus and most patients with type 2 diabetes mellitus receiving CII in critical care setting require transitioning to a subcutaneous insulin regimen. Several models have been proposed for transition from insulin infusion to subcutaneous insulin therapy. In general, the initial dose and distribution of subcutaneous insulin at the time of transition can be determined by extrapolating the intravenous insulin requirement over the preceding 6 to 8 hours to a 24-hour period. The total daily dose of insulin can also be calculated based on body weight, which could emulate general subcutaneous weight-based insulin guidelines. It is important that consideration be given to a patient’s nutritional status and medications, with continuation of glucose monitoring to guide ongoing adjustments in the insulin dose, because changes in insulin sensitivity can occur during acute illness.

Recent literature on transition methodology discusses 2 general principles behind safe and effective transition from intravenous to subcutaneous insulin: (1) the 24-hour insulin requirement is extrapolated from an appropriately selected hourly insulin rate and (2) the subcutaneous insulin program is designed to fit a patient’s nutrition program. Strategies to find the basal dose include taking 80% of the total amount of insulin used in the preceding 24 hours and splitting it into basal and prandial insulin to maintain glucose in the optimal range. To prevent recurrence of hyperglycemia during the transition to subcutaneous insulin, it is important to allow an overlap of 1 to 2 hours between discontinuation of intravenous insulin and the administration of subcutaneous insulin. For patients who are not receiving significant amount of calories, the basal dose can be given in 1 single, long-acting, daily insulin (eg, glargine or detemir) dose or 2 intermediate-acting insulin (neutral protamine Hagedorn [NPH]) doses every 12 hours. Short-acting insulins (regular) or rapid-acting insulins (aspart, glulisine, and lispro) can be added as needed depending on nutritional intake and glucose levels.

Most patients with stress hyperglycemia and with normal HbA1c levels who have been on CII in the ICU at rates less than or equal to 1 to 2 U/h at the time of transition do not require a scheduled subcutaneous insulin regimen. Many of these patients can be treated with correction insulin to determine if they require scheduled subcutaneous insulin.

Insulin Therapy in the Non–Critical Care Setting

Subcutaneous insulin is the preferred therapeutic agent for BG control in the non-ICU setting. No single insulin regimen meets the needs for all subjects with hyperglycemia. Scheduled subcutaneous insulin therapy with basal or intermediate acting insulin given once or twice a day in combination with short-acting or rapid-acting insulin administered before meals is preferred as an effective and safe strategy for glycemic management in non–critically ill patients. Subcutaneous insulin programs should address the 3 components of insulin requirement: basal (what is required in the fasting state), nutritional (what is required for glucose elevations or to dispose of glucose in hyperglycemia) (Fig. 3).

The practice of discontinuing oral diabetes medications and/or insulin therapy and starting sliding scale insulin (SSI) results in undesirable levels of hypoglycemia and hyperglycemia. The SSI regimen, although straightforward and easy to use, is faced...
with several challenges that include inadequate coverage of glycemic excursions and insulin stacking. The authors recently reported the results of a prospective, randomized multicenter trial comparing the efficacy and safety of a basal/bolus insulin regimen with basal bolus regimen and SSI in patients with type 2 diabetes mellitus admitted to general medicine wards. The authors found that among 130 insulin-naïve patients with an admission BG level between 140 mg/dL and 400 mg/dL, the use of basal-bolus insulin had greater improvement in BG control than sliding scale alone. A BG target of less than 140 mg/dL was achieved in 66% of patients in the glargine plus glulisine group and 38% in the sliding scale group. One-fifth of patients treated with an SSI without a basal component had persistently elevated BG level greater than 240 mg/dL during the hospital stay. The incidence of hypoglycemia, defined as a BG level less than 3.3 mmol/L (<60 mg/dL), was low in this study. In general surgery patients, the recent RAndomized Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients with Type 2 Diabetes Undergoing General Surgery (RABBIT 2 Surgery) trial compared the efficacy and safety of basal bolus regimen to SSI in 211 patients with type 2 diabetes mellitus. Study outcomes included differences in daily glucose levels and a composite of postoperative complications, including wound infection, pneumonia, respiratory failure, acute renal failure, and bacteremia. Patients were randomized to receive basal bolus regimen with glargine and glulisine (starting dose of 0.5 U/kg/d) or SSI (4 times/d). The basal bolus regimen resulted in significant improvement in glucose control and a reduction in the frequency of the composite complications. The results of these trials indicate that basal bolus regimen is preferred to SSI and results in improved glycemic control and lower rate of hospital complications in general medical and surgical patients with type 2 diabetes mellitus.

An open-label, controlled, multicenter trial randomly assigned 130 medical patients with type 2 diabetes mellitus to receive detemir once daily and aspart before meals with NPH and regular insulin twice daily. Both treatment regimens resulted in significant improvements in inpatient glycemic control with a glucose target of less than 140 mg/dL before meals achieved in 45% in the detemir/aspart group and in 48% of NPH/regular insulin group. Hypoglycemia (<60 mg/dL) was observed in approximately one-fourth of patients treated with detemir/aspart and NPH/regular insulin during the hospital stay. There were no differences in length of hospital stay or mortality between groups. Thus, it seems that similar improvement in glycemic control can be achieved with either basal bolus therapy with detemir/aspart or with NPH/regular insulin in general medical patients with type 2 diabetes mellitus.

Initial insulin doses of basal bolus protocols vary widely from 0.3 U/kg/d to 1.5 U/kg/d, although only the initial starting dose range between 0.4 U/kg/d and 0.5 U/kg/d, divided into a balanced basal bolus regimen, has been studied prospectively. A case-control analysis of 1990 patients with diabetes using hypoglycemia as a tool to identify insulin dose ranges based on risk reported that a total daily dose of 0.6 U/kg seems to be the threshold below which the odds of hypoglycemia are low and that doses more than 0.79 U/kg/d are associated with a 3-fold higher odds of hypoglycemia than doses lower than 0.2 U/kg/d. Thus, it may be reasonable to consider lower initial daily doses (<0.3 U/kg) in patients with hypoglycemia risk factors (eg, elderly patients and those with renal insufficiency). Approximately 50% of the calculated dose can be administered as basal insulin and 50% as prandial or nutritional insulin in divided doses administered with meals. Daily or twice-daily adjustment of the initial insulin doses is required to achieve and maintain glucose targets and to avoid hypoglycemia in nearly all cases of hyperglycemia during hospitalization.
RECOGNITION AND MANAGEMENT OF HYPOGLYCEMIA IN THE
HOSPITAL SETTING

Hypoglycemia is defined as any glucose level less than 3.9 mmol/L (70 mg/dL). Severe hypoglycemia has been defined by many investigators as less than 2.2 mmol/L (40 mg/dL). The incidence of severe hypoglycemia among the different trials ranged between 5% and 28%, depending on the intensity of glycemic control in the ICU, whereas rates from trials using subcutaneous insulin in non–critically ill patients range from less than 1% to 33%. The key predictors of hypoglycemic events in hospitalized patients include older age, greater illness severity, diabetes, and the use of oral glucose-lowering medications and insulin. In-hospital processes of care that contribute to risk for hypoglycemia include unexpected changes in nutritional intake that are not accompanied by associated changes in the glycemic management regimen (eg, cessation of nutrition for procedures and adjustment in the amount of nutritional support), interruption of the established routine for glucose monitoring, deviations from the established glucose control protocols, and failure to adjust therapy when glucose is trending down or steroid therapy is tapered.

Increasing evidence from observational studies and clinical trials indicates that the development of severe hypoglycemia is independently associated with increased risk of mortality. The odds ratio (95% CI) for mortality associated with 1 or more episodes was 2.28 (1.41–3.70, *P* = .0008) among a cohort of 5365 patients admitted to a mixed medical-surgical ICU. In a larger cohort of more than 60,000 patients, hypoglycemia was associated with longer ICU stay and greater hospital mortality, especially for patients with more than 1 episode of hypoglycemia. In patients with acute myocardial infarction, those with hypoglycemia had higher mortality compared with patients without hypoglycemic event (12.7% vs 9.6%, *P* = .03), and the relationship between hypoglycemia and mortality was similar in patients with and without known history of diabetes. Despite these observations, the direct causal effect of iatrogenic hypoglycemia on adverse outcome is still debatable. In a recent study assessing the impact of iatrogenic versus spontaneous hypoglycemia in critical illness, Kosiborod and colleagues reported that spontaneous hypoglycemia is associated with higher in-hospital mortality and that insulin-induced hypoglycemia was not associated with increased risk of death compared with subjects without hypoglycemia. Similarly, a recent study of 31,970 patients also reported that hypoglycemia is associated with increased in-hospital mortality (hazard ratio 1.67; 95% CI, 1.33–2.09); however, the greater risk was limited to patients with spontaneous hypoglycemia and not to patients with drug-associated hypoglycemia. After adjustment for patient comorbidities, the association between spontaneous hypoglycemia and mortality was eliminated. These studies raised the possibility that hypoglycemia is a marker of disease burden rather than a direct cause of death.

**SUMMARY**

Based on currently available literature, insulin should not be viewed passively as an optional therapy in the hospital. Current evidence supports proactive, scheduled insulin regimens for any patient with consistent hyperglycemia, not only patients with known diabetes and/or who were taking insulin before hospitalization. The proactive approach considers that hyperglycemia is at once both deleterious and related to the endocrinology of the stressed state and requires patient-tailored and situation-tailored insulin therapy. Exposed patients with newly identified hyperglycemia may be at the highest risk of hyperglycemia-related morbidity and mortality. In consideration of the hospital environment, namely unpredictable changes in care and patient condition, imprecision of glucose monitoring, and the variable effects of interventions and nutrition therapy on glycemia, moderate glycemic goals that
seek to control glucose while avoiding hypoglycemia are prudent for the majority of hospitalized patients.

Acknowledgments

Dr Umpierrez is supported by research grants from the National Institutes of Health (UL1 RR025008) (Atlanta Clinical and Translational Science Institute) and American Diabetes Association (7-03-CR-35).

References


Fig. 1.
Pathogenesis of hyperglycemia. Hyperglycemia during acute illness results from increased hepatic glucose production and impaired glucose use in peripheral tissues. Excess counterregulatory hormones (glucagon, cortisol, catecholamines, and growth hormone) increase lipolysis and protein breakdown (proteolysis) and impaired glucose use by peripheral tissues. Hyperglycemia causes osmotic diuresis that leads to hypovolemia decreased glomerular filtration rate and worsening hyperglycemia. At the cellular level, increased BG levels results in mitochondrial injury by generating reaction oxygen species and endothelial dysfunction by inhibiting nitric oxide production. Hyperglycemia increases levels of inflammatory cytokines, such as TNF-α; IL-6, leading to immune system dysfunction; and plasminogen activator inhibitor-1 and fibrinogen, causing platelet aggregation and hyper-coagulable state. These changes can eventually lead to increased risk of infection, impaired wound healing, multiple organ failure, prolonged hospital stay, and death.
Fig. 2.
Example of insulin infusion protocol. Essential elements that increase protocol success of CII are (1) rate adjustment considers the current and previous glucose value and the current rate of insulin infusion, (2) rate adjustment considers the rate of change (or lack of change) from the previous reading, and (3) frequent glucose monitoring.

**Continuous Insulin Infusion Protocol**

**Target BG = 110 – 180 mg/dL**

- If bolus is ordered by MD, give 0.1 unit/kg (IV push).
- Calculate initial IV Insulin infusion rate as follows:
  
  \[ \text{BG (mg/dL) / 100} = \text{units/hour} = \text{mL/hour} \text{ (rounded to nearest 0.1 Unit)} \]

- Check BG in 1 hour, titrate per protocol below. (Insulin drip= 1 unit/mL)

<table>
<thead>
<tr>
<th>BG (mg/dL)</th>
<th>WITH ANY INCREASE in BG from prior BG</th>
<th>BG DECREASE LESS than 30 mg/dL from prior BG</th>
<th>BG DECREASE GREATER than or EQUAL to 30 mg/dL from prior BG</th>
</tr>
</thead>
<tbody>
<tr>
<td>241 or greater</td>
<td>Increase rate by 2 units/hr</td>
<td>Increase rate by 3 units/hr</td>
<td>NO CHANGE</td>
</tr>
<tr>
<td>211 – 240</td>
<td>Increase rate by 2 units/hr</td>
<td>Increase rate by 2 units/hr</td>
<td>NO CHANGE</td>
</tr>
<tr>
<td>181 – 210</td>
<td>Increase rate by 1 unit/hr</td>
<td>Increase rate by 1 unit/hr</td>
<td>NO CHANGE</td>
</tr>
<tr>
<td>141 – 180</td>
<td>NO CHANGE</td>
<td>NO CHANGE</td>
<td>NO CHANGE</td>
</tr>
<tr>
<td>110 – 140</td>
<td>NO CHANGE</td>
<td>NO CHANGE</td>
<td>Decrease rate by 1/2</td>
</tr>
<tr>
<td>91 – 109</td>
<td>Decrease rate by 1/2</td>
<td>Decrease rate by 1/2</td>
<td>1. HOLD insulin drip. 2. Check BG q 1 hour: Restart infusion rate at 1/2 prior infusion rate when BG greater than 180 mg/dL</td>
</tr>
<tr>
<td>71 – 90</td>
<td>1. HOLD insulin drip. 2. Check BG q 1/2 hour until BG is greater than 90 mg/dL, then check BG q 1 hour. 3. Restart prior infusion rate at 1/2 rate when BG greater than 180 mg/dL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>70 or Less</td>
<td>1. HOLD insulin drip. 2. Give IV D50 3. Repeat BG q 15 minutes until BG greater than 70 mg/dL, then check BG q 30 minutes until BG greater than 90 mg/dL. 4. BG greater than 90 mg/dL, check BG q 1 hour; Restart infusion at 1/2 prior infusion rate when BG greater than 180 mg/dL</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

When BG reaches target (BG=110-180 mg/dL) for 2 consecutive readings, check BG q 2 hours.

**Critical Values:**
- Treat for BG less than 45 mg/dL or greater than 450 mg/dL per protocol then Notify MD.
- If patient’s BG levels continue to increase after 2 interventions, notify MD.
Subcutaneous Insulin orders

1. Check capillary blood glucose (BG)
   □ Before meals and at bedtime  □ Before meals, bedtime, and 03:00
   □ Every 6 hours (patients on continuous tube feeds or NPO)

2. Scheduled Subcutaneous Insulin (Recommend use ½ daily dose as basal and other ½ as prandial)

<table>
<thead>
<tr>
<th>Basal Insulin</th>
<th>BREAKFAST</th>
<th>LUNCH</th>
<th>DINNER</th>
<th>BEDTIME</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NPH</td>
<td></td>
<td>NPH</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Glargine</td>
<td></td>
<td>Glargine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Detemir</td>
<td></td>
<td>Detemir</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Prandial Insulin**†</th>
<th>BREAKFAST</th>
<th>LUNCH</th>
<th>DINNER</th>
<th>BEDTIME</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NPH</td>
<td></td>
<td>NPH</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Glargine</td>
<td></td>
<td>Glargine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Detemir</td>
<td></td>
<td>Detemir</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Continuous feeds or NPO (q4h)</th>
<th>0800</th>
<th>1200</th>
<th>1800</th>
<th>2400</th>
</tr>
</thead>
<tbody>
<tr>
<td>Give Insulin units Regular insulin</td>
<td>Give Insulin units Regular insulin</td>
<td>Give Insulin units Regular insulin</td>
<td>Give Insulin units Regular insulin</td>
<td></td>
</tr>
</tbody>
</table>

*Give NPH insulin: twice daily. Glargine: once daily, and Detemir: Once or twice daily
** Give lispro/aspart immediately before or after meals. Give regular insulin 30 minutes prior to meals
† Patients with inconsistent oral intake: RN may reduce prandial dose of aspart based on the percent of meal ingested (e.g. if 50% of calories are ingested, give 50% of the dose)

3. Supplemental Correction Insulin (regular, lispro, aspart, glulisine) ADD to dose of scheduled insulin.

**†† Check appropriate column below and cross out other columns

BEFORE MEALS add supplemental insulin dose (0 of units) from table below to the scheduled insulin dose.

BEDTIME: Give ½ of supplemental sliding scale insulin dose at bedtime

<table>
<thead>
<tr>
<th>Blood Glucose (mg/dL)</th>
<th>Insulin Sensitive</th>
<th>Usual</th>
<th>Insulin Resistant</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;141</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>&gt;141-180</td>
<td>1</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>181-220</td>
<td>2</td>
<td>4</td>
<td>6</td>
</tr>
<tr>
<td>221-260</td>
<td>4</td>
<td>6</td>
<td>8</td>
</tr>
<tr>
<td>261-300</td>
<td>6</td>
<td>8</td>
<td>10</td>
</tr>
<tr>
<td>301-350</td>
<td>8</td>
<td>10</td>
<td>12</td>
</tr>
<tr>
<td>351-400</td>
<td>10</td>
<td>12</td>
<td>14</td>
</tr>
<tr>
<td>&gt;400</td>
<td>12</td>
<td>14</td>
<td>16</td>
</tr>
</tbody>
</table>

Fig. 3.
Use of insulin ordering forms to prescribe basal/bolus insulin programs. Insulin order forms are useful to illustrate and encourage the use of the 3 components of a patient-tailored insulin program (e.g., basal, nutritional, and supplemental/correction).
Table 1

Important counterregulatory hormones and mediators of inflammation known to be associated with acute hyperglycemia

<table>
<thead>
<tr>
<th>Glucoregulatory Hormone</th>
<th>Metabolic Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cortisol</td>
<td>↑ Skeletal muscle IR, ↑ lipolysis → ↑ gluconeogenesis</td>
</tr>
<tr>
<td>Epinephrine</td>
<td>↑ Skeletal muscle IR, ↑ gluconeogenesis and glycogenolysis, ↑ Lipolysis, ↓ insulin secretion from β cell</td>
</tr>
<tr>
<td>Norepinephrine</td>
<td>↑ Gluconeogenesis (at high levels), ↑ lipolysis</td>
</tr>
<tr>
<td>Glucagon</td>
<td>↑ Gluconeogenesis and glycogenolysis</td>
</tr>
<tr>
<td>Growth hormone</td>
<td>↑ Skeletal muscle IR, ↑ gluconeogenesis, ↑ lipolysis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Inflammation Mediators</th>
<th>Metabolic Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>TNF-α</td>
<td>↑ Skeletal and hepatic IR</td>
</tr>
<tr>
<td>IL-1</td>
<td>↑ Skeletal and hepatic IR</td>
</tr>
<tr>
<td>IL-6</td>
<td>↑ Skeletal and hepatic IR</td>
</tr>
<tr>
<td>IL-18</td>
<td>↑ Skeletal and hepatic IR</td>
</tr>
<tr>
<td>FFAs</td>
<td>↑ Skeletal and hepatic IR, ↑ gluconeogenesis</td>
</tr>
</tbody>
</table>

Abbreviation: IR, insulin resistance.
### Table 2

Summary of key randomized clinical trials designed to test effect of glycemic control in critical illness

<table>
<thead>
<tr>
<th>Author</th>
<th>Population</th>
<th>Design/Endpoint</th>
<th>No. of Patients</th>
<th>Achieved Glycemic Endpoints (Mean ± SD [mg/dL])</th>
<th>Hospital Mortality OR (95% CI)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Van den Berghe et al.</td>
<td>Surgical, mechanical ventilation</td>
<td>Randomized 80–110 vs 180–200 mg/dL Research RN-titrated insulin per protocol</td>
<td>1548</td>
<td>Daily 153 ± 33 (Mean) Control; Daily 103 ± 19 (P&lt;.001)</td>
<td>0.64 (0.45–0.91)</td>
<td>High use of parenteral dextrose (TPN); stopped early for benefit</td>
</tr>
<tr>
<td>Van den Berghe et al.</td>
<td>Medical, expected ICU stay &gt;72 h</td>
<td>Randomized Bedside RN-titrated per paper protocol</td>
<td>1200</td>
<td>Daily 153 ± 31 (Mean) Control; Daily 111 ± 29 (P&lt;.001)</td>
<td>0.89 (0.71–1.13)</td>
<td>High use of parenteral dextrose (TPN)</td>
</tr>
<tr>
<td>Presier GLUCONTROL</td>
<td>Medical, surgical</td>
<td>Randomized 80–110 vs 140–180 mg/dL Bedside RN-titrated per protocol</td>
<td>1078</td>
<td>144 (IQR 128–162) median— all values Control; 117 (IQR 108–130) median—all values</td>
<td>1.27 (0.94–1.7)</td>
<td>Stopped early for hypoglycemia; many protocol violations</td>
</tr>
<tr>
<td>NICE-SUGAR</td>
<td>Medical, surgical</td>
<td>Randomized 80–110 vs 140–180 mg/dL, Adjusted via computerized algorithm</td>
<td>6104</td>
<td>144 ± 23 (Mean) Control; 115 ± 18 (P&lt;.001)</td>
<td>28-Day mortality: 1.09 (0.96–1.23) 90-Day mortality: 1.14 (1.02–1.28)</td>
<td>GC group did not achieve target</td>
</tr>
<tr>
<td>Brunkhorst et al. (VISEP)</td>
<td>Sepsis</td>
<td>Randomized 80–110 vs 180–200 mg/dL Bedside RN-titrated per Van den Berghe protocol</td>
<td>537</td>
<td>Median—daily 138 (IQR 111–184) Control; Median—daily 130 (IQR 108–167) (P=.05)</td>
<td>0.94 (0.63–1.38)</td>
<td>GC group did not achieve target; study stopped early for hypoglycemia risk; underpowered</td>
</tr>
<tr>
<td>De La Rosa et al.</td>
<td>Medical, surgical</td>
<td>Randomized 80–110 vs 180–200 mg/dL Bedside RN-titrated per protocol</td>
<td>504</td>
<td>Median—all values 149 (IQR 124–180) Control; Median—all values 120 (IQR 110–134) (P&lt;.001)</td>
<td>1.09 (0.75–1.54)</td>
<td>GC group did not achieve target; underpowered</td>
</tr>
<tr>
<td>Arabi et al.</td>
<td>Medical, surgical</td>
<td>Randomized 80–110 vs 180–200 mg/dL Bedside RN-titrated per paper protocol</td>
<td>523</td>
<td>171 ± 34 (Mean) Control; 115 ± 18 (P&lt;.0001)</td>
<td>0.78 (0.53–1.13)</td>
<td>Underpowered</td>
</tr>
<tr>
<td>Farah et al.</td>
<td>Medical with &gt;3-day LOS</td>
<td>Randomized 110–140 vs 140–200 mg/dL</td>
<td>89</td>
<td>174 ± 20 (Mean) Control; 142 ± 14</td>
<td>28-Day mortality: 54% vs 46% (P&lt;.05)</td>
<td>Underpowered; vascular morbidity lower with GC</td>
</tr>
<tr>
<td>Gray and Perdrizet</td>
<td>Surgical, excluded patients with diabetes</td>
<td>Randomized 80–120 mg/dL vs 180–220 mg/dL</td>
<td>61</td>
<td>179 ± 61 (Mean) Control; 125 ± 36 mg/dL; daily mean value lower on each day</td>
<td>21% vs 11% (P=.05)</td>
<td>Underpowered; lower nosocomial infection incidence with GC</td>
</tr>
<tr>
<td>Mackenzie et al.</td>
<td>Medical, surgical, trauma</td>
<td>Randomized 72–108 vs 190–198 mg/dL</td>
<td>240</td>
<td>144 ± 40 Time-weighted mean; 113 ± 22 Time-weighted mean</td>
<td>40% vs 32% (P=.28)</td>
<td>Stopped early due to financial limits</td>
</tr>
</tbody>
</table>
Abbreviations: GC, glycemic control; IQR, interquartile; IV, intravenous; LOS, length of stay; OR, odds ratio; RN, registered nurse; SQ, subcutaneous; TPN, total parenteral nutrition.

*Hospital mortality unless otherwise specified. OR <1 indicates benefit due to glycemic control. Outcome prevalence written as control group vs glycemic control.